murine autologous anti-CD19 CART cells / Beijing Boren Hospital - LARVOL DELTA

Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children (clinicaltrials.gov) - P2 | N=2 | Completed | Sponsor: Beijing Boren Hospital | Recruiting ➔ Completed | N=100 ➔ 2

Enrollment change • IO biomarker • Trial completion • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • ABL1 • CD19

Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Beijing Boren Hospital | Trial completion date: Nov 2022 ➔ Nov 2024 | Trial primary completion date: May 2022 ➔ May 2024

CAR T-Cell Therapy • IO biomarker • Preclinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • ABL1 • CD19

Auto Hematopoietic Stem Cell Transplantation Combined with Another Target Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Failure of Murinized CD19-CAR-T Therapy (ASH 2021) - "Aims : To prolong relapse-free survival, we combined ASCT and another target humanized CAR-T cells to treat r/r B-NHL patients failed to murinized CD19-CAR-T cells therapy with either CD22 or CD20 antigen expression on tumor cell.The safety and efficacy will be evaluated...B-cell aplasia was documented in all cases(7/7,100%) of CD20-CART group and two cases(2/5,40%) of CD22-CART group during the follow-up... CRS is manageable and has no influence on hematopoiesis reconstitution.With current protocol, complication was mild and encouraging disease control was found. ASCT combined with another target humanized CAR-T therapy is a safe and effective salvage strategy for r/r B-NHL after failure of murinized CD19-CAR-T. Long-term follow-up is needed."

CAR T-Cell Therapy • IO biomarker • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Transplantation • CD19 • CD22 • CD34 • IFNG • IL6 • TP53

[VIRTUAL] THE SALVAGE TREATMENT OF HUMANIZED-CD19 CAR-T CELLS FOR RELAPSED B-ALL AFTER PRIOR MURINIZED-CD19 CAR-T CELL THERAPY (EHA 2021) - "All patients accepted fludarabine and/or cyclophosphamide before cell infusion. Conclusion The salvage treatment of humanized CD19-CART cells resulted in a 67% CR in CD19-positive relapsed B-ALL patients who had a prior murinized CD19-CART therapy, and transplantation followed-by hCD19-CART allowed 90% CR patients to obtain a remission of 2.4-22 months. The prognosis of NR patients was still poor."

CAR T-Cell Therapy • IO biomarker • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Inflammation • Leukemia • Oncology • Pediatrics • Transplantation • CD19 • CD22 • TP53

[VIRTUAL] SALVAGE TREATMENT WITH HUMANIZED CART CELLS FOR DIFFUSED LARGE B-CELL LYMPHOMA AFTER THE FAILURE OF MURINE ANTI-CD19-CART CELL THERAPY (EHA 2020) - "Among them, there were 17 I-II CRS, 3 III CRS, and no treatment-related deaths. Conclusion It can be seen from this study that relapsed and refractory diffuse large B cell lymphoma after the failure of murine anti CD19-CART cell therapy, the treatment of humanized CART cells targeting B cell markers again, still has a certain effect, and the safety is good."

CAR T-Cell Therapy • IO Biomarker • Preclinical • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: Beijing Boren Hospital

Clinical • IO Biomarker • New P2 trial